Media coverage
3
Media coverage
Title First global patient takes part in trial of new drug to treat rare inflammatory muscle disease Degree of recognition International Media name/outlet Manchester NIHR BRC Media type Web Country/Territory United Kingdom Date 9/01/20 URL https://www.manchesterbrc.nihr.ac.uk/news-and-events/first-global-patient-takes-part-trial-new-drug-treat-rare-inflammatory-muscle-disease/ Persons James Lilleker Title Global first for Salford team in rare disease study Degree of recognition International Media name/outlet Northern Care Alliance Research and Innovation Media type Web Country/Territory United Kingdom Date 9/12/19 Description Congratulations to the Salford Royal Core Research Team, Professor Hector Chinoy (PI) and Dr James Lilleker for dosing the first patient globally in a study testing the efficacy and safety of a new treatment for a rare inflammatory muscle disease. Producer/Author NCA URL https://www.ncaresearch.org.uk/news/global-first-for-salford-team-in-rare-disease-study/ Persons James Lilleker, Hector Chinoy Title Ra Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Zilucoplan for IMNM Degree of recognition International Media name/outlet RaPharma and Business Wire Media type Web Country/Territory United Kingdom Date 4/12/19 Description CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 4, 2019-- Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the initiation of dosing in its Phase 2 clinical trial of zilucoplan for the treatment of immune-mediated necrotizing myopathy (IMNM). URL https://rapharma.gcs-web.com/news-releases/news-release-details/ra-pharmaceuticals-announces-dosing-first-patient-phase-2 Persons James Lilleker, Hector Chinoy